Authors
Latest:
Evaluating the Efficacy of Paxlovid in High-Risk Patients with Pre-Existing ImmunityJohn McLaughlin, PhD, examines high-risk individuals with prior SARS-CoV-2 immunity and presents that Paxlovid reduces the risk of hospitalization, death, and severe symptoms, highlighting its ongoing value for high-risk patients in a post-peak pandemic landscape.
Latest:
Considerations for Antimicrobial Stewardship While Optimizing Therapy for a Patient With HIVHere is a case study involving a patient with the virus and the clinical approach in thinking about appropriate treatment while keeping stewardship in mind.
Latest:
Internal Tremors: Adding to the List of Long COVID SymptomsInternal tremors are a newly recognized and troubling symptom of Long COVID, experienced by over one-third of participants in a Yale-based study
Latest:
Discussing Outpatient COVID-19 TreatmentsHere is a look at some of the treatment alternatives, which can offer simpler logistics and cost considerations.
Latest:
The Role of Rifampin in Bone and Joint InfectionsIn the latest column from the Society of Infectious Diseases Pharmacists (SIDP), here is a discussion on the use of rifampin as an adjunctive antibiotic treatment for patients with diabetic foot osteomyelitis.
Latest:
Clarametyx Biosciences Initiates Phase 2a Trial for CMTX-101 in Cystic Fibrosis PatientsDavid Richards emphasized the therapy’s potential to enhance antibiotic effectiveness by targeting bacterial biofilms, a significant challenge in treatment.
Latest:
Updates and Controversies in Necrotizing Soft Tissue InfectionsChanges in microbiology and antimicrobial resistance patterns warrant reevaluation of our current therapies for this condition.
Latest:
Education and Advocacy in DC: The PLF C Diff Summit and Lobby DayThe Peggy Lillis Foundation's (PLF) CEO and Cofounder Christian John Lillis talks about these important events happening in the capital at the end of this month.
Latest:
Targeting C difficile with Oxygen-Based TherapyLarry Sutton, MD, PhD, discussed how oxygen affects C. difficile and provides anti-inflammatory effects in the gut, with potential applications for gastrointestinal diseases.
Latest:
Antibiotic Stewardship Programs Help Curb Superbug Threat by Leveraging DataThe OASIS platform will help outpatient facilities use prescribing data to improve patient care.
Latest:
A Personnel Problem: We Need More Antimicrobial Researchers, Infectious Disease CliniciansA decreasing number of researchers and open positions for infectious disease clinicians and limited residency matches are underlying issues that should be addressed to meet the needs around antimicrobial development and clinical care. Amesh Adalja, MD, FIDSA, discusses some of the challenges behind it.
Latest:
A Clinician’s Perspective on Rebyota for Recurrent C Diff TreatmentTimothy Ritter, MD, provides his insights on using the live biotherapeutic product and what both patients and clinicians can expect in terms of safety and efficacy.
Latest:
The Business Sector's Advocacy to Maintain Funding for HIV Prevention, Research, TreatmentA coalition of employers, the US Business Action to End HIV, sent a letter to Congress outlining the continued need for support from the federal government.
Latest:
ALLIANCE Study: B/F/TAF Achieves Sustained HIV and HBV SuppressionAnchalee Avihingsanon, MD, PhD presents results showing 95.4% HIV RNA suppression and 86.6% HBV DNA suppression after 48 weeks of B/F/TAF in HIV-HBV co-infected patients.
Latest:
How a Prodrug Approach May Aid In Antimalarial DevelopmentSesh Sundararaman, MD, PhD, discusses his findings and how this approach can be triggered to minimize undesirable treatment features and open the door to newer treatment possibilities.
Latest:
What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility TestingThe Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
Latest:
Nonventilator Hospital-Acquired Pneumonia: Epidemiology, Prevention, and Where It Is NowThe management of hospital-acquired pneumonia requires use of preventive bundles, mitigative of risk factors, and prompt diagnosis with initiation of treatment when highly suspected.
Latest:
Advancing STOP2030 Treatment in Global HealthAlejandro Krolewiecki, MD discusses the path to regulatory approval, collaboration with global health organizations, and the role of partnerships in scaling up the new treatment for neglected tropical diseases.
Latest:
The Impact of Widespread RSV Vaccination and Quantifying ResultsIn the fourth and final episode, the clinicians speak of the need for greater uptake of the RSV vaccines, overcoming an "RSV identity crisis," and the potential ancillary benefit of reducing bacterial infections.
Latest:
Fluoroquinolone Safe for Treating Severe Refractory M Pneumoniae PneumoniaInvestigators asked the children’s parents about the history of musculoskeletal-related disease, observed the children’s gait, and performed physical examinations.
Latest:
Navigating the Challenges of CMS AUR Reporting Mandates: Penalties, Progress, and PitfallsThe long-term benefits of antimicrobial use and resistance (AUR) reporting is about improving patient care and combating resistance.
Latest:
Examining the HIV Treatment PipelineA review of selected investigational long-active treatment options for HIV.
Latest:
Does Slow Viral Clearance and Viral Rebound During Infection Contribute to Long COVID?Annie Antar, MD, PhD, offers insights around her research on her findings on this subject.
